Plus Therapeutics Taps Kiora Pharmaceuticals Exec as Chief Development Officer
Event summary
- Eric J. Daniels, M.D., MBA, joins Plus Therapeutics as Chief Development Officer effective April 20, 2026.
- Daniels brings over 20 years of experience in clinical development, regulatory strategy, and business development.
- Former Chief Development Officer at Kiora Pharmaceuticals, Daniels will oversee Plus Therapeutics' CNS oncology pipeline.
- Plus Therapeutics focuses on precision diagnostics and radiopharmaceuticals for central nervous system cancers.
The big picture
The appointment of Eric J. Daniels as Chief Development Officer signals Plus Therapeutics' push to accelerate its clinical pipeline, particularly in the targeted radiotherapeutic space for CNS cancers. Daniels' extensive background in biotechnology and his track record at Kiora Pharmaceuticals suggest a strategic focus on both clinical and commercial viability. This move comes at a critical juncture for Plus Therapeutics as it aims to differentiate its approach in a competitive oncology market.
What we're watching
- Pipeline Acceleration
- How Daniels' experience will impact the speed of REYOBIQ and other CNS oncology programs.
- Strategic Partnerships
- Whether Plus Therapeutics can leverage Daniels' network to secure new collaborations.
- Regulatory Strategy
- The effectiveness of Daniels' regulatory approach in advancing Plus Therapeutics' clinical pipeline.
Related topics